Market Cap 8.75B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 872.73
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,871,900
Avg Vol 1,571,794
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 97%
Beta 0.05
Analysts Sell
Price Target $106.00

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 an...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
FE123
FE123 Oct. 24 at 12:04 PM
$VKTX Druckenmiller wants the Buyout over $100!! like $VRNA
1 · Reply
shopno
shopno Oct. 20 at 11:35 PM
$IOVA that's exactly right! Another factor comes in play is competition or drug superiority. For instance, $VRNA got a superior COPD drug, and got 600-700% growth at BO since FDA approval in Q2 2024. For $MDGL , price had been muted even with solid revenue growth as the firstever MASH drug due to upcoming competitions and the fact that it's not most effective drug. For $IOVA the decline from post FDA approval took some time, but take a look at $TNXP -- another very poorly managed stock -- infamous for FOREVER reverse splitting. I had been in TNXP only since last reverse-split, and sold positions as it went 1000% on HYPE. And then it LOST 70% value since FDA approval -- even BEFORE the drug is launched. Just because TNXP had another F-grade managements, many investors who got in after the FDA approval in August dumped due to fear of failure launch by a low caliber CEO.
2 · Reply
YungBullHOLLA
YungBullHOLLA Oct. 16 at 11:53 AM
$VRNA miss yall Holla
1 · Reply
FE123
FE123 Oct. 13 at 1:53 PM
$VKTX Druckenmiller wants $106 like his $VRNA Buyout!!
1 · Reply
FE123
FE123 Oct. 10 at 5:44 PM
$VKTX Shorts Don’t Bet against Druckenmiller!! He wants another $VRNA type Buyout!! Better Cover!!
0 · Reply
domandterrie
domandterrie Oct. 10 at 2:48 PM
$VRNA do you know when options will be cashed out?
1 · Reply
TAG01
TAG01 Oct. 10 at 2:13 PM
$VRNA great run from 15 to 107 got in because of @Stocktor who kept me patient at CCXI. i just took up position at $IMRX because they have a treatment for pancreatic cancer which in 2a tials have kept 86% alive compared to 47% standart treatment at 9 months.. second reason I went there is because Thomas Schall went there and he was the CEO of CCXI another small molecule inhibitor. any way listed to Thomas earnings call and that guy is a rock star. will likely be long road but they have cash from recent public offering till 2029 which get them through phase 3. And sanofi just took up 25M position as well. which tells me its a BO candidate. GLTA love to hear other opinions.
1 · Reply
zippewa
zippewa Oct. 10 at 12:15 PM
$VRNA any former vrna longs getting on the board with CGTX?
1 · Reply
Datum
Datum Oct. 9 at 10:56 PM
$VRNA i keep coming back to this idea that $MRK is undervalued. Lots of talk that Keytruda needs a replacement, which is fair, but it seems like Ohtuvayre has a reasonably good chance of achieving that. Keytruda did $29.5b in sales for 2024. Based on Veronas original numbers, ohtuvayre would need to hit 10% of its market to do the same sales figure. 833,333 x 35,400 = $29.5b 833,333 / 8.6m = 10% of TAM. The last presentation I head from verona, they specifically said that 10% to 15% should be possible. I know this isnt necessarily a banger investment like verona was, but theres a great chance ohtuvayre fills the gap that keytruda is leaving. There is easily 25% upside in the next year $MRK in my opinion.
0 · Reply
zippewa
zippewa Oct. 9 at 9:15 PM
$VRNA anyone know when this will cash at $107?
3 · Reply
Latest News on VRNA
Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 3 months ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK


Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 3 months ago

Two big reasons why buying Verona was crucial for Merck


Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 3 months ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK


Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 3 months ago

Merck to acquire Verona Pharma for $10 billion

MRK


Verona Pharma: A Blockbuster Franchise In The Making

Jun 10, 2025, 1:17 AM EDT - 4 months ago

Verona Pharma: A Blockbuster Franchise In The Making


Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 3:45 PM EDT - 6 months ago

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript


Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:31 PM EST - 8 months ago

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript


Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:47 AM EST - 1 year ago

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript


Top 3 Health Care Stocks That May Crash In August

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In August

CAH CPRX


Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 1:15 PM EDT - 1 year ago

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript


Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRDN


FE123
FE123 Oct. 24 at 12:04 PM
$VKTX Druckenmiller wants the Buyout over $100!! like $VRNA
1 · Reply
shopno
shopno Oct. 20 at 11:35 PM
$IOVA that's exactly right! Another factor comes in play is competition or drug superiority. For instance, $VRNA got a superior COPD drug, and got 600-700% growth at BO since FDA approval in Q2 2024. For $MDGL , price had been muted even with solid revenue growth as the firstever MASH drug due to upcoming competitions and the fact that it's not most effective drug. For $IOVA the decline from post FDA approval took some time, but take a look at $TNXP -- another very poorly managed stock -- infamous for FOREVER reverse splitting. I had been in TNXP only since last reverse-split, and sold positions as it went 1000% on HYPE. And then it LOST 70% value since FDA approval -- even BEFORE the drug is launched. Just because TNXP had another F-grade managements, many investors who got in after the FDA approval in August dumped due to fear of failure launch by a low caliber CEO.
2 · Reply
YungBullHOLLA
YungBullHOLLA Oct. 16 at 11:53 AM
$VRNA miss yall Holla
1 · Reply
FE123
FE123 Oct. 13 at 1:53 PM
$VKTX Druckenmiller wants $106 like his $VRNA Buyout!!
1 · Reply
FE123
FE123 Oct. 10 at 5:44 PM
$VKTX Shorts Don’t Bet against Druckenmiller!! He wants another $VRNA type Buyout!! Better Cover!!
0 · Reply
domandterrie
domandterrie Oct. 10 at 2:48 PM
$VRNA do you know when options will be cashed out?
1 · Reply
TAG01
TAG01 Oct. 10 at 2:13 PM
$VRNA great run from 15 to 107 got in because of @Stocktor who kept me patient at CCXI. i just took up position at $IMRX because they have a treatment for pancreatic cancer which in 2a tials have kept 86% alive compared to 47% standart treatment at 9 months.. second reason I went there is because Thomas Schall went there and he was the CEO of CCXI another small molecule inhibitor. any way listed to Thomas earnings call and that guy is a rock star. will likely be long road but they have cash from recent public offering till 2029 which get them through phase 3. And sanofi just took up 25M position as well. which tells me its a BO candidate. GLTA love to hear other opinions.
1 · Reply
zippewa
zippewa Oct. 10 at 12:15 PM
$VRNA any former vrna longs getting on the board with CGTX?
1 · Reply
Datum
Datum Oct. 9 at 10:56 PM
$VRNA i keep coming back to this idea that $MRK is undervalued. Lots of talk that Keytruda needs a replacement, which is fair, but it seems like Ohtuvayre has a reasonably good chance of achieving that. Keytruda did $29.5b in sales for 2024. Based on Veronas original numbers, ohtuvayre would need to hit 10% of its market to do the same sales figure. 833,333 x 35,400 = $29.5b 833,333 / 8.6m = 10% of TAM. The last presentation I head from verona, they specifically said that 10% to 15% should be possible. I know this isnt necessarily a banger investment like verona was, but theres a great chance ohtuvayre fills the gap that keytruda is leaving. There is easily 25% upside in the next year $MRK in my opinion.
0 · Reply
zippewa
zippewa Oct. 9 at 9:15 PM
$VRNA anyone know when this will cash at $107?
3 · Reply
shopno
shopno Oct. 9 at 7:13 AM
$TNXP As you claim doing your research -- which any sane investors should do -- specifically for larger allocation, learn first that TNXP has only patent protection till 2034. Only 9 years till Tonmya patents to expire globally! As such launch speed ALWAYS matters for EVERY biotech. As you day-dream for a $10B cap for clown-led TNXP, check the revenue growth trajectory for $VRNA and $MDGL, and COMEBACK here to compare starting Q1 2026. VRNA and MDGL got approval in end of Q2 and Q1 respectively. Just in 13 months later, VRNA got acquired for $10B. And MDGL market cap now $10B. When you check the sales trajectory, you would see MDGL fetched $200M+ just in 5th quarter after approval, with ~1,400% YoY growth in Q2 2025. Since VRNA got acquired too early, it didn't have a YoY growth to report, but by 4th quarter of launch it crossed $100M+. I have been in both, and felt even $10B a cheap BO for VRNA, as optimistic valuation would have been $15-20B long term.
2 · Reply
PoeDallas
PoeDallas Oct. 9 at 5:40 AM
$VRNA Thanks for the ride. been a lovely profit !
0 · Reply
FE123
FE123 Oct. 8 at 7:21 PM
$VKTX Druckenmiller wants his next $VRNA type Buyout!!
0 · Reply
shopno
shopno Oct. 8 at 5:53 AM
$TNXP reference to $MDGL or $VRNA brought up here as some of the blind TNXP-cults were having org@sm seeing TNXP to similar $10B market cap in second year of fda approval. These cults hyped up TNXP market cap to reach $10-20B, some clown worshipper even mentioned holding 15,000 TNXP shares before fda-approval, and was talking about $200-400 stock price as a sure thing post-approval. Current stock price is the GREATEST SLAP to those blind cults.
2 · Reply
Homebody1
Homebody1 Oct. 8 at 12:12 AM
$VRNA Has anyone got cashed out yet by their brokerage firm...hoping to see this tomorrow morning.
2 · Reply
shopno
shopno Oct. 7 at 11:55 PM
$TNXP why cash on hand matters when the company is losing money everyday, and company is too sluggish to launch a pill effectively! Check how quick $MDGL and $VRNA got their launch last year. One got acquired for $10B, and MDGL would fetch even a higher price tag. Compare that to this clown-led company who cannot even share the drug price months after approval!
0 · Reply
Sukitt
Sukitt Oct. 7 at 5:10 PM
$VRNA Good luck ensifentrine. Continue to grow. Thank you for the ride.
0 · Reply
Rascal7777777
Rascal7777777 Oct. 7 at 2:07 PM
$VRNA we love 😘 u.
0 · Reply
Jakeipedia
Jakeipedia Oct. 7 at 1:36 PM
$VRNA absolutely killing! Pleasure reading this board from all you bulls and longs.
0 · Reply
Rascal7777777
Rascal7777777 Oct. 7 at 6:08 AM
$VRNA well maybe ST will keep this board open like ccxi
0 · Reply
Putnamdan
Putnamdan Oct. 6 at 10:43 PM
$VRNA thats all folks. And now I can retire
1 · Reply
marked0ne
marked0ne Oct. 6 at 9:53 PM
$VRNA bye folks, i will (and already am) sincerely missing this board….
0 · Reply